T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

  1. Albert Beckers1
  1. 1CHU de Liège-University of Liège, Liège, Belgium
  2. 2Université Catholique de Louvain, Brussels, Belgium
  3. 3CHU Jean Minjoz, Besancon, France
  4. 4CHU Marseille, Marseille, France
  5. 5Université Libre de Bruxelles, Bruxelles, Belgium
  6. 6Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila and Neuroendocrinology, Neuromed IRCCS, Pozzilli, Italy
  7. 7CHU Angers, Angers, France
  8. 8CHU Strasbourg, Strasbourg, France
  9. 9CHU Lyon, Lyon, France
  10. 10Universitätsklinikum Erlangen, Erlangen, Germany
  11. 11CHU Bocage, Dijon, France
  12. 12CHU Reims, Reims, France
  13. 13Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
  14. 14Faculty of Medicine, Erciyes University, Kayseri, Turkey
  15. 15University of Genova, Genova, Italy
  16. 16Hospital Universitario Gregorio Marañon, Madrid, Spain
  17. 17Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), IIB-Sant Pau, ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
  18. 18CHU Bordeaux, Bordeaux, France
  19. 19Charles University, Prague, Czech Republic
  20. 20CHU Nancy, Nancy, France
  21. 21Moscow Regional Research and Clinical Institute, Russia
  22. 22Kazan State Medical Academy, Kazan, Russia
  23. 23Centre Pierre et Marie Curie, Algiers, Algeria
  24. 24Center of Endocrinology & Metabolism, Bamberg, Germany
  1. Correspondence should be addressed to A Beckers; Email: albert.beckers{at}chu.ulg.ac.be
  1. Figure 1

    Correlation between the visual assessment of T2-weighted signal intensity and the ROI measurement.

  2. Figure 2

    Responses of random GH (A), IGF-1% (B) and volume (C) to SSA primary treatment depending on T2-weighted signal intensity.

  3. Figure 3

    Correlation between quantitative T2-weighted signal intensity of adenomas and their response to SSA in terms of GH (A), IGF-1% (B) and volume (C). GM, grey matter.

  4. Figure 4

    IGF-1% reduction under treatment depending on T2-weighted signal at diagnosis. The dotted line corresponds to 100% of the ULN.

  5. Figure 5

    Examples of volume and IGF-1 (% ULN) responses to SSA treatment in GH-secreting pituitary adenomas with different T2-weighted signals.

| Table of Contents
Editor's Choice